Red Light Therapy for Hip Pain & Bursitis

Hip pain is among the most common musculoskeletal complaints, affecting an estimated 10-15% of adults over 60 in the UK. The causes range from osteoarthritis and trochanteric bursitis to labral tears, post-surgical recovery, and referred pain from the lumbar spine. Conventional management typically involves NSAIDs, physiotherapy, corticosteroid injections, and in advanced cases, hip replacement surgery.

Red light therapy (photobiomodulation) offers a non-invasive, drug-free adjunct, though the hip presents unique challenges due to the depth of the joint and surrounding structures. This guide examines the evidence, explains why wavelength selection matters more here than for superficial conditions, and provides evidence-based protocols.

Why hip pain is challenging for light therapy

The hip joint sits deep within the body. The femoral head and acetabulum are typically 4-8 cm below the skin surface, covered by substantial layers of muscle (gluteus maximus, medius, and minimus), fascia, and subcutaneous tissue. This depth presents a fundamental challenge for photobiomodulation.

Red light at 630-660 nm penetrates only 2-3 mm into tissue. Even near-infrared (NIR) at 810-850 nm — which penetrates significantly deeper — reaches approximately 3-5 cm in most studies (Huang et al., 2009, Dose-Response). This means that for intra-articular hip pathology (cartilage degeneration, labral damage, synovial inflammation), the light may not reach the target tissue in sufficient quantity to produce a direct photobiomodulatory effect.

However, several structures involved in hip pain are more accessible:

• Trochanteric bursa — sits approximately 1-3 cm beneath the skin over the greater trochanter, well within NIR penetration range
• Gluteal tendons — the gluteus medius and minimus tendons at the greater trochanter are accessible to NIR wavelengths
• Superficial hip musculature — the outer layers of the gluteal muscles and tensor fasciae latae can be reached
• Periarticular soft tissues — the joint capsule and surrounding ligaments, whilst deep, are partially accessible from anterior and lateral approaches

The practical implication: red light therapy is more likely to help with periarticular hip conditions (bursitis, tendinopathy, muscular pain) than with deep intra-articular pathology (advanced cartilage loss, labral tears).

Trochanteric bursitis (greater trochanteric pain syndrome)

Greater trochanteric pain syndrome (GTPS) — previously known as trochanteric bursitis — is one of the most common causes of lateral hip pain, affecting 10-25% of the general population. It involves inflammation of the trochanteric bursa and/or degeneration of the gluteal tendons at their insertion on the greater trochanter (Segal et al., 2007, Archives of Physical Medicine and Rehabilitation).

Why PBM is well-suited for GTPS

The trochanteric bursa and gluteal tendon insertions are relatively superficial compared to the hip joint itself. In most individuals, the greater trochanter is palpable through the skin, with the overlying tissue typically 1-3 cm thick. This places the target structures well within the effective range of NIR wavelengths.

Evidence

Direct RCTs examining PBM specifically for GTPS are limited, but the broader evidence base provides strong support:

Tumilty et al. (2010, Photomedicine and Laser Surgery) conducted a systematic review of LLLT for tendinopathy and found moderate evidence for benefit, particularly when adequate doses were used. The review highlighted that studies using WALT-recommended doses (4-8 J per treatment point for tendons) showed significantly better outcomes than those using lower doses.

Bjordal et al. (2006, Photomedicine and Laser Surgery) demonstrated in a meta-analysis that LLLT at NIR wavelengths reduced pain and improved function in tendinopathy, with effect sizes comparable to corticosteroid injections at 6-week follow-up — without the risk of tendon weakening associated with repeated steroid injections.

Haslerud et al. (2015, BMJ Open) reviewed LLLT for shoulder tendinopathy and found clinically significant pain reduction and functional improvement. Whilst the shoulder is a different joint, the pathological mechanism (tendon degeneration + bursal inflammation) is closely analogous to GTPS.

Mechanism

PBM addresses GTPS through several pathways:

1. Anti-inflammatory action — reduces TNF-alpha, IL-1beta, and PGE2 in the bursa and peritendinous tissue (Hamblin, 2017, AIMS Biophysics)
2. Tendon healing — stimulates tenocyte proliferation and collagen synthesis, promoting tendon repair (Tumilty et al., 2010)
3. Pain modulation — inhibits nociceptive signalling in local nerve endings (Chow et al., 2011, BMJ Open)
4. Improved microcirculation — tendons have poor blood supply; NIR-mediated vasodilation can enhance nutrient delivery and waste removal

Hip osteoarthritis

Hip osteoarthritis (OA) affects approximately 11% of adults over 45 in the UK and is the primary indication for hip replacement surgery. The disease involves progressive cartilage degradation, subchondral bone changes, synovial inflammation, and periarticular muscle weakness.

Evidence

The evidence for PBM in hip OA is less robust than for knee OA, primarily because the hip joint is deeper and fewer studies have been conducted.

Stausholm et al. (2019, BMJ Open) published a major systematic review and meta-analysis of LLLT for knee OA, demonstrating statistically and clinically significant reductions in pain and improvements in function when WALT-recommended doses were used. Whilst this study focused on the knee, the underlying pathological mechanisms are identical, and the anti-inflammatory effects of PBM are not joint-specific.

Hegedus et al. (2009, Photomedicine and Laser Surgery) specifically studied LLLT for knee OA using 830 nm continuous wave laser and reported significant improvements in pain, joint stiffness, and functional capacity at 4 J/cm2 per treatment point. The anti-inflammatory mechanism demonstrated in this study applies equally to hip synovitis.

Ip (2015, Lasers in Medical Science) examined combined LLLT and exercise therapy for hip OA and reported greater improvement in pain and function compared to exercise alone, though the study had a small sample size.

Honest assessment

For hip OA, the evidence should be rated as moderate for periarticular effects and preliminary for intra-articular effects. PBM can reasonably be expected to:

• Reduce inflammation in the joint capsule and periarticular tissues
• Improve pain through neurological modulation
• Enhance muscle recovery in the gluteal and hip flexor muscles weakened by OA

It is less likely to:

• Reverse cartilage damage (the joint surface is too deep for meaningful light penetration in most individuals)
• Replace the need for hip replacement in advanced OA
• Match the pain relief of corticosteroid injections for severe flares

Hip replacement rehabilitation

Post-surgical rehabilitation is an area where PBM has stronger mechanistic and clinical support. Following total hip arthroplasty (THA), the target tissues — surgical wound, surrounding soft tissue inflammation, and muscle healing — are all within reach of NIR wavelengths.

Evidence

Tumilty et al. (2016, Physiotherapy Theory and Practice) reviewed PBM for post-surgical rehabilitation and found consistent evidence for reduced pain, swelling, and improved functional recovery when PBM was applied as an adjunct to standard physiotherapy.

Bjordal et al. (2006) demonstrated that PBM accelerates wound healing and reduces post-operative inflammation, both directly relevant to hip replacement recovery.

Leal-Junior et al. (2015, Lasers in Medical Science) showed in a meta-analysis that PBM before and after exercise enhanced muscle recovery and reduced DOMS (delayed onset muscle soreness), suggesting potential benefit during the intensive physiotherapy phase of hip replacement rehabilitation.

Practical application

For post-hip-replacement rehabilitation, PBM can be applied to:

1. The surgical wound — using red wavelengths (660 nm) at low doses (2-4 J/cm2) once the wound is closed (not over open wounds without medical supervision)
2. Periarticular soft tissues — using NIR wavelengths (810-850 nm) at 4-8 J/cm2 to reduce inflammation and promote tissue healing
3. Gluteal and quadriceps muscles — using NIR at 4-6 J/cm2 to support muscle recovery alongside physiotherapy exercises

Important: Always obtain clearance from your orthopaedic surgeon before using any device near a hip replacement. Whilst there is no evidence that PBM interferes with prosthetic components, post-surgical treatment should be coordinated with your medical team.

Recommended protocols

For trochanteric bursitis / GTPS

Parameter	Recommendation
Wavelength	810-850 nm (NIR essential)
Irradiance	50-100 mW/cm2
Dose	4-8 J per treatment point, 3-4 points around the greater trochanter
Session duration	8-15 minutes
Frequency	Daily for first 2 weeks; then 3-5 times weekly
Course	6-12 weeks minimum
Treatment position	Lying on unaffected side; device positioned directly over the greater trochanter at 2-6 inch distance

For hip osteoarthritis

Parameter	Recommendation
Wavelength	810-850 nm (NIR essential; red wavelengths will not penetrate)
Irradiance	50-200 mW/cm2 (higher irradiance helps compensate for tissue depth)
Dose	6-10 J per treatment point, 4-6 points around the hip (anterior, lateral, posterior)
Session duration	15-20 minutes
Frequency	5-7 times weekly during acute flare; 3-5 times weekly for maintenance
Course	8-16 weeks to assess response; ongoing if beneficial
Treatment position	Multiple positions needed — lying supine (anterior hip), side-lying (lateral), and prone (posterior)

For post-hip-replacement rehabilitation

Parameter	Recommendation
Wavelength	660 nm (wound) + 810-850 nm (deep tissue)
Dose	2-4 J/cm2 (wound); 4-8 J per point (periarticular)
Frequency	Daily during first 6 weeks; then 3-5 times weekly
Start timing	After wound closure; with surgeon approval
Course	Throughout rehabilitation period (typically 3-6 months)

Device considerations for hip treatment

The hip’s depth and the size of the treatment area make device selection particularly important:

Panel size

A panel with at least 60 cm vertical coverage (equivalent to BioMax 300 or larger) is recommended. Smaller handheld devices can work but require multiple repositioning and longer total treatment times to cover all treatment points around the hip.

Wavelength requirements

NIR is non-negotiable for hip conditions. A red-only device (630-660 nm) cannot reach the periarticular structures, let alone the joint itself. Ensure your device includes 810-850 nm LEDs. Dual-wavelength panels (660 nm + 850 nm) provide the broadest utility — red for any superficial wound or skin components, NIR for the deep tissue targets.

Irradiance

Higher irradiance is more important for hip treatment than for facial or superficial applications. At tissue depths of 2-5 cm, a significant proportion of the incident light is absorbed and scattered before reaching the target. A panel delivering 100 mW/cm2 at the surface may deliver only 5-10 mW/cm2 at 3 cm depth. Starting with higher surface irradiance helps ensure a therapeutic dose reaches the target tissue.

Treatment distance

For hip conditions, closer is better. Position the device 2-6 inches from the skin, directly over the treatment area. Increased distance reduces irradiance quadratically (inverse square law), which is particularly problematic when treating deep structures.

Complementary approaches

Red light therapy for hip conditions works best as part of a comprehensive approach:

• Physiotherapy and exercise — strengthening the gluteal muscles (particularly gluteus medius) is the cornerstone of GTPS management and a critical component of hip OA and post-replacement rehabilitation
• Weight management — every kilogram of body weight exerts 3-6 times that force through the hip joint during walking; weight reduction meaningfully reduces hip load
• NSAIDs — for acute flares, short-term NSAID use remains effective; PBM may allow reduced NSAID use over time
• Corticosteroid injections — for severe GTPS or OA flares, injections provide rapid relief that PBM cannot match; PBM may help maintain improvement between injections

When to seek medical attention

Do not rely on red light therapy alone if you experience:

• Sudden, severe hip pain (possible fracture or avascular necrosis)
• Inability to bear weight on the affected leg
• Hip pain with fever (possible septic arthritis — a medical emergency)
• Progressive loss of range of motion despite conservative treatment
• Night pain that wakes you from sleep (may indicate serious pathology)

The bottom line

Red light therapy offers a reasonable, evidence-supported adjunct for hip pain — with the critical caveat that effectiveness varies significantly depending on the specific condition and its anatomical depth.

For trochanteric bursitis and gluteal tendinopathy, where the target tissues are relatively superficial, the evidence and the physics align well. NIR wavelengths at adequate doses can reach the affected structures, and the anti-inflammatory and tissue-healing mechanisms are directly relevant.

For hip osteoarthritis, the benefit is more likely periarticular (reducing capsular inflammation, improving muscle function) than intra-articular (reversing cartilage damage). This is still clinically meaningful — pain and function can improve even without structural change — but expectations should be calibrated accordingly.

For post-hip-replacement rehabilitation, PBM as an adjunct to physiotherapy has good mechanistic support and a growing evidence base.

In all cases, NIR wavelengths (810-850 nm) are essential, adequate dosing is critical, and PBM should complement rather than replace medical management and physiotherapy.

References

• Bjordal JM, Couppe C, et al. (2006). Low-level laser therapy for tendinopathy: evidence of a dose-response pattern. Physical Therapy Reviews, 6(2), 91-99.
• Chow RT, Armati PJ (2011). Photobiomodulation: implications for anesthesia and pain relief. Photomedicine and Laser Surgery, 29(5), 299-305.
• Hamblin MR (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337-361.
• Haslerud S, Magnussen LH, et al. (2015). The efficacy of low-level laser therapy for shoulder tendinopathy: a systematic review and meta-analysis of randomized controlled trials. Physiotherapy Research International, 20(2), 108-125.
• Hegedus B, Viharos L, et al. (2009). The effect of low-level laser in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial. Photomedicine and Laser Surgery, 27(4), 577-584.
• Huang YY, Sharma SK, et al. (2009). Biphasic dose response in low level light therapy. Dose-Response, 7(4), 358-383.
• Ip D (2015). Does addition of low-level laser therapy (LLLT) in conservative care of knee arthritis successfully postpone the need for joint replacement? Lasers in Medical Science, 30(9), 2335-2339.
• Leal-Junior EC, Vanin AA, et al. (2015). Effect of phototherapy (low-level laser therapy and light-emitting diode therapy) on exercise performance and markers of exercise recovery: a systematic review with meta-analysis. Lasers in Medical Science, 30(2), 925-939.
• Segal NA, Felson DT, et al. (2007). Greater trochanteric pain syndrome: epidemiology and associated factors. Archives of Physical Medicine and Rehabilitation, 88(8), 988-992.
• Stausholm MB, Naterstad IF, et al. (2019). Efficacy of low-level laser therapy on pain and disability in knee osteoarthritis: systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open, 9(10), e031142.
• Tumilty S, Munn J, et al. (2010). Low level laser treatment of tendinopathy: a systematic review with meta-analysis. Photomedicine and Laser Surgery, 28(1), 3-16.